AlphaStocks
5.9
Consider Buy

Resmed Inc (RMD)

As of Sep 20, 2026, Resmed Inc (RMD) scores 5.9/10 on AlphaStocks' five-model composite, #58 of 168 Health Care stocks. At $225, RMD trades 21% below its model fair value of $287.

Health Care / Health Care Equipment

S&P 500

$225.12

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 5 of 5 models — high confidence

Data as of Sep 20, 2026

#58out of 168 in Health Care

Is RESMED INC a Good Investment in 2026?

RESMED INC (RMD) scores 5.9 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates RESMED INC as Strong (8/9). The Lynch model is the least favorable, rating it Neutral. RESMED INC currently trades 21% below its estimated fair value of $287. RESMED INC ranks #58 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E23.7ROE23.6Market Cap33BDiv Yield1.0

Estimated Fair Value

$286.6921% below

Trading below estimated fair value. EPS grew 37% year-over-year. ROE of 24% signals strong profitability. P/E of 24x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

8/9

Buffett

Strong

Business quality & competitive moat

Graham

Neutral

Significantly above fair value

Lynch

Neutral

PEG 1.5 · Fast Grower

Greenblatt

Attractive

Earnings yield 5.7% · ROC 55%

Frequently Asked Questions

Is RESMED INC (RMD) a good investment?
As of Sep 20, 2026, Resmed Inc (RMD) scores 5.9/10 on AlphaStocks' five-model composite, #58 of 168 Health Care stocks. At $225, RMD trades 21% below its model fair value of $287. That is a middle-of-the-pack score with no strong signal either way.
What is RESMED INC's Piotroski F-Score?
RESMED INC's Piotroski F-Score status is Strong. The raw score is 8/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is RMD overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $287, RMD appears undervalued. The stock currently trades 21% below its estimated fair value. Trading below estimated fair value. EPS grew 37% year-over-year. ROE of 24% signals strong profitability. P/E of 24x is moderate for this quality level.
How does RMD compare to other Health Care stocks?
RESMED INC ranks #58 out of 168 stocks in the Health Care sector, placing it in the top 35% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about RMD?
AlphaStocks evaluates RMD using five proven investment models. Piotroski: Strong; Buffett: Strong; Graham: Neutral; Lynch: Neutral; Greenblatt Magic Formula: Attractive. These models are combined into a single composite score of 5.9/10.

Similar Stocks

INSPUFPTBDX

Compare RMD with

INSP vs RMDRMD vs UFPTBDX vs RMDRMD vs VAL

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer